The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis of patient and study characteristics

Cancer Medicine
Lauren C BylsmaJon P Fryzek

Abstract

Systemic cancer therapies may induce infusion reactions (IRs) or hypersensitivities. Metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies, including cetuximab and panitumumab, may be subject to these reactions. We conducted a meta-analysis to estimate the IR incidence in this population and identify variations in this incidence by patient or study characteristics. A systematic review was conducted to identify observational studies or clinical trials of mCRC patients treated with anti-EGFR therapies that reported occurrences of IRs, hypersensitivity, or allergy/anaphylaxis. The objective of the study was to estimate the incidence of IRs. Random effects models were used to meta-analyze the incidence of IRs overall and stratified by therapy type, study design, geographic location, RAS or KRAS mutation status, grade of reaction severity, and terminology used to describe the reaction. The pooled estimate for IR incidence was 4.9% (95% confidence interval: 3.6%-6.5%). Lower-grade reactions were more common than higher-grade reactions overall and the incidence of reactions among cetuximab patients was nearly four times that of panitumumab patients (6.1% vs 1.6%). IRs occur in approximately 5% of mCRC patients ...Continue Reading

References

Sep 1, 1986·Controlled Clinical Trials·R DerSimonian, N Laird
Sep 29, 2001·Journal of Clinical Epidemiology·J A Sterne, M Egger
Oct 26, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·K M Zanotti, M Markman
Jun 12, 2002·Current Treatment Options in Oncology·H L Kindler, K L Shulman
Jul 12, 2002·Statistics in Medicine·Julian P T Higgins, Simon G Thompson
Mar 1, 2006·International Immunopharmacology·David J Hamrock
Aug 21, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bert H O'NeilRichard M Goldberg
Jan 10, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Leila G Saldanha
Dec 4, 2009·American Journal of Therapeutics·Carla Kurkjian, Shivaani Kummar
Mar 31, 2010·Clinical Journal of Oncology Nursing·Wendy H Vogel
Oct 20, 2011·BMJ : British Medical Journal·Julian P T HigginsUNKNOWN Cochrane Statistical Methods Group
Dec 16, 2011·Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology·Aung Ko WinMark A Jenkins
Jan 17, 2013·Therapeutic Advances in Medical Oncology·Teresa TroianiFortunato Ciardiello
Aug 31, 2013·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Veronica MezzanoMariana Castells
Sep 5, 2013·Therapeutic Advances in Gastroenterology·Sing Yu MoorcraftDavid Cunningham
Sep 13, 2013·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Ashley Wong, Brigette B Y Ma
Jun 21, 2015·Journal of Crohn's & Colitis·Lev LichtensteinBatia Weiss

❮ Previous
Next ❯

Citations

Sep 30, 2020·JCO Oncology Practice·Amy M SionJohn M Kaczmar

❮ Previous
Next ❯

Software Mentioned

Cochrane Risk of Bias Assessment Tool
EpidStat
SimulStat
Comprehensive Meta ‐ Analysis

Related Concepts

Related Feeds

Anaphylaxis

Anaphylaxis is a serious allergic reaction that is rapid in onset and may cause death.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.